Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 222 participants.
Also called NCT05359263
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 222 participants
- Sponsor
- Registry
-
NCT05359263
-
- Other papers using this trial's data
- Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Recruiting
Technical summary
Registry record NCT05359263. Randomized; triple masking; primary purpose treatment. Start 2022-06-08 (actual); primary completion 2025-02-18 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
- Acronym
- DECODE-CKD
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Dapagliflozin 10 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tor Biering-Sørensen
Record details
- Record id
cardio:ct-nct05359263- Content hash
d1e7e20eedae5596fd322117c37d5389adf8f5469051f74a873b115000440917